| 引用本文: |
周挺,李洪超,马爱霞,等.加拿大药品统一审评制度及价格管理体系简析[J].中国卫生经济,2018,(2):94-96.[点击复制] |
.The Introduction of Canada’s Common Drug Review and Price Management System[J].CHINESE HEALTH ECONOMICS,2018,(2):94-96.[点击复制] |
|
| 摘要: |
| 2003年加拿大开始实行药品统一审评制度，从国家层面为各省完成新药的统一审评，并给出列入省级药品报销目录的推荐意见。为控制药品费用的不合理增长，1988年加拿大成立专利药价格审评委员会（PMPRB），负责全国专利药的价格管理，此后各省在药品统一审评推荐意见的基础上，结合PMPRB制定的参考价格确定专利药医保支付标准。仿制药则主要通过省级谈判和仿制药定价倡议控制支付价格。本文通过分析加拿大药品统一审评制度及价格管理体系，为我国医保目录的准入及价格谈判提供参考。 |
| 关键词: |
| DOI： |
|
| 基金项目: |
|
| The Introduction of Canada’s Common Drug Review and Price Management System |
|
| () |
| Abstract: |
| Canada Common Drug Review (CDR) was established in 2003, it undertakes reviews of new drugs and provide formulary listing recommendations for all provinces ’ governments. PMPRB was established in 1988 to manage the national patent drugs’ prices. The determination of provinces’ patent drugs reimbursement payment standard s were on the consideration of CDR’s recommendations and PMPRB’s reference prices. Generic drugs’ price was controlled by province’s price negotiation and generic value price initiative. This study introduced the Canada CDR and price management system to provide reference for China reimbursement d rug list access and price negotiation. |
| Key words: |
